Company intelligence / Profile preview

Beijing Delifore Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Delifore Pharmaceutical Technology is a clinical-stage biotechnology company focused on the research and development of innovative small molecule drugs. Operating as a subsidiary of InventisBio, the company specializes in therapeutic areas such as oncology and metabolic disorders. Its most advanced program, D-0502, is an oral selective estrogen receptor degrader (SERD) currently undergoing Phase 3 clinical trials for ER-positive, HER2-negative breast cancer. The company also maintains a pipeline of metabolic candidates, including the URAT1 inhibitor D-0120 for the treatment of gout and hyperuricemia.

Therapeutic areas: RheumatologyMetabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Delifore Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Delifore Pharmaceutical Technology.

Explore the full profile